Supernus Pharmaceuticals SUPN Common stock, shares authorized (in shares)
Common stock, shares authorized (in shares) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's common stock, shares authorized (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's common stock, shares authorized (in shares)?
- Supernus Pharmaceuticals (SUPN) reported common stock, shares authorized (in shares) of $130M in Q1 2026.
- How has Supernus Pharmaceuticals's common stock, shares authorized (in shares) changed year-over-year?
- Supernus Pharmaceuticals's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $130M to $130M.
- What is the long-term trend for Supernus Pharmaceuticals's common stock, shares authorized (in shares)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $130M to $130M.